tradingkey.logo

Saudi FDA Grants Accelerated Approval To Immunitybio’S Anktiva® For Non-Muscle Invasive Bladder Cancer With Carcinoma In-Situ

ReutersJan 14, 2026 1:33 PM

- Immunitybio Inc IBRX.O:

  • SAUDI FDA GRANTS ACCELERATED APPROVAL TO IMMUNITYBIO’S ANKTIVA® FOR NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN-SITU

  • IMMUNITYBIO- ENROLLMENT IN RANDOMIZED TRIAL OF ANKTIVA IN BCG NAÏVE NMIBC PATIENTS AHEAD OF SCHEDULE WITH FULL ENROLLMENT ANTICIPATED BY Q2 2026

  • IMMUNITYBIO INC: ANKTIVA BLA SUBMISSION TARGETED BY YEAR-END

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI